Clinical Trial Update: Phase 2 Study: OBI-833/OBI-821 Maintenance for Globo H+ Advanced Biliary Tract Cancer After Gemcitabine/Cisplatin [Phase 1]

View source ↗

Summary

A Phase 2 maintenance trial of OBI-833 and OBI-821 for Globo H-positive advanced biliary tract cancer after gemcitabine/cisplatin is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• OBI-821
• OBI-833

Snippet

Sponsor: Chang Gung Memorial Hospital | Conditions: Cholangiocarcinoma, Chemotherapy Effect | Phase 1 | Status: NOT_YET_RECRUITING